Neuronostics

Neuronostics is revolutionizing the diagnosis and prognosis of neurological conditions. Leveraging the power of mathematical modeling, Neuronostics develops novel biomarkers that pave the way for faster diagnoses and more effective treatments.

Neuronostics's initial clinical indication, BioEP, represents an entirely new digital biomarker for epilepsy. By using background EEG data and mathematical modeling, BioEP predicts the likelihood of seizures. This innovative BioEP risk score supports clinical diagnostic and prognostic decisions related to epilepsy. Neuronostics envisions a future where digital biomarkers are routinely used in neurology centers worldwide, creating a more proactive and anticipatory model of care that transforms neurological healthcare and radically improves the lives of individuals at risk of or living with neurological conditions.

With a commitment to innovation and patient care, Neuronostics is dedicated to advancing the field of neurology. We invite the manager of Neuronostics to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and impact.